In 2018, Dr. Saar Gill and Dr. Michael Klichinsky, CAR-T cell therapy experts from the University of Pennsylvania, founded Carisma Therapeutics with a focus on developing CAR-M therapy for cancer treatment.190 In 2020, they published a paper in the journal Nature Biotechnology introducing a HER2-targeting CAR-M. The gene discussed is ERBB2; the disease is cancer.